The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines

Journal of Psychopharmacology

Volumn 24, Issue 5, 2010, Pages 757-765

  García Gutiérrez, María S ^a   Manzanares, Jorge ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Alprazolam; AM251; Amnesic; Anxiety; Cannabinoid CB1 receptor; Sedative; WIN 55,212 stimulated 35S GTP3 binding autoradiography

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CANNABINOID 1 RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); SULFUR 35;

AMNESIA; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; ATAXIA; AUTORADIOGRAPHY; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DENTATE GYRUS; DRUG INHIBITION; ELECTRIC SHOCK; HIPPOCAMPUS; KNOCKOUT MOUSE; LONG TERM MEMORY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEDATION; SHORT TERM MEMORY; TRANQUILIZING ACTIVITY;

ALPRAZOLAM; AMNESIA; AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CA1 REGION, HIPPOCAMPAL; GTP-BINDING PROTEIN GAMMA SUBUNITS; HYPNOTICS AND SEDATIVES; MALE; MICE; MICE, INBRED ICR; NERVOUS SYSTEM DISEASES; ORGAN SPECIFICITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SEVERITY OF ILLNESS INDEX;

EID: 77952163415     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106910     Document Type: Article

References (51)

1. Arborelius L., Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160: 1-12.
2. Arevalo C., de Miguel R., Hernandez-Tristan R. (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70: 123-131.
3. Atack JR, Hutson PH, Collinson N., et al. (2005) Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Brit J Pharmacol 144: 357-366.
4. Azad SC, Eder M., Marsicano G., Lutz B., Zieglgansberger W., Rammes G. (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learning & Memory (Cold Spring Harbor, NY) 10: 116-128.
5. Berrendero F., Maldonado R. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 163: 111-117.
6. Bortolato M., Campolongo P., Mangieri RA, et al. (2006) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31: 2652-2659.
7. Chen Y., Constantini S., Trembovler V., Weinstock M., Shohami E. (1996) An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma 13: 557-568.
8. Corchero J., Fuentes JA, Manzanares J. (1999 a) Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 64: 905-911.
9. Corchero J., Romero J., Berrendero F., et al. (1999 b) Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Mol Brain Res 67: 148-157.
10. Cota D., Steiner MA, Marsicano G., et al. (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary- adrenal axis function. Endocrinology 148: 1574-1581.
11. Crawley J., Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167-170.
12. Dias R., Sheppard WF, Fradley RL, et al. (2005) Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25: 10682-10688.
13. File SE, Kenny PJ, Cheeta S. (2000) The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66: 65-72.
14. Gaetani S., Cuomo V., Piomelli D. (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs ? Trends in Mole Med 9: 474-478.
15. Haller J., Bakos N., Szirmay M., Ledent C., Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. European J Neurosci 16: 1395-1398.
16. Haller J., Matyas F., Soproni K., et al. (2007) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. European J Neurosci 25: 2445-2456.
17. Haller J., Varga B., Ledent C., Freund TF (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15: 299-304.
18. Hoffman AF, Lupica CR (2000) Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479.
19. Kathuria S., Gaetani S., Fegley D., et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
20. Katona I., Rancz EA, Acsady L., et al. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: 9506-9518.
21. Katona I., Sperlagh B., Sik A., et al. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
22. Katona I., Urban GM, Wallace M., et al. (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628-5637.
23. Low K., Crestani F., Keist R., et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science (New York, NY) 290: 131-134.
24. Manzanares J., Corchero J., Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839: 173-179.
25. Marco EM, Perez-Alvarez L., Borcel E., et al. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behavioural Pharmacology 15: 21-27.
26. McDonald AJ, Mascagni F. (2001) Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107: 641-652.
27. McKernan RM, Rosahl TW, Reynolds DS, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nature Neurosci 3: 587-592.
28. Moreira FA, Kaiser N., Monory K., Lutz B. (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54: 141-150.
29. Naderi N., Haghparast A., Saber-Tehrani A., et al. (2008) Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 89: 64-75.
30. Navarro M., Hernandez E., Munoz RM, et al. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8: 491-496.
31. Patel S., Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311.
32. Pawelzik H., Hughes DI, Thomson AM (2002) Physiological and morphological diversity of immunocytochemically defined parvalbumin- and cholecystokinin- positive interneurones in CA1 of the adult rat hippocampus. J Comparative Neurol 443: 346-367.
33. Paxinos G., Franklin K. (2001) The Mouse Brain in Stereotaxic Coordinates. San Diego, Academic Press.
34. Rezayat M., Roohbakhsh A., Zarrindast MR, Massoudi R., Djahanguiri B. (2005) Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav 84: 775-782.
35. Rodgers RJ, Evans PM, Murphy A. (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16: 405-413.
36. Rodriguez de Fonseca F., Roberts AJ, Bilbao A., Koob GF, Navarro M. (1999) Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 20: 1109-1114.
37. Romero J., Berrendero F., Manzanares J., et al. (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308.
38. Roohbakhsh A., Moghaddam AH, Massoudi R., Zarrindast MR (2007) Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 34: 223-229.
39. Rossi S., De Chiara V., Musella A., et al. (2008) Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 28: 7284-7292.
40. Rubino T., Sala M., Vigano D., et al. (2007) Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9- tetrahydrocannabinol in rats. Neuropsychopharmacology 32: 2036-2045.
41. Rutkowska M., Jamontt J., Gliniak H. (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58: 200-206.
42. Scherma M., Medalie J., Fratta W., et al. (2008) The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54: 129-140.
43. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16: 8057-8066.
44. Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5ĝ€2 -[gamma-[35S]thio]-triphosphate binding. Proceed National Acad Sci, USA 92: 7242-7246.
45. Steiner MA, Wotjak CT (2008) Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170: 397-432.
46. Thomson AM, Bannister AP, Hughes DI, Pawelzik H. (2000) Differential sensitivity to Zolpidem of IPSPs activated by morphologically identified CA1 interneurons in slices of rat hippocampus. European J Neurosci 12: 425-436.
47. Tsigos C., Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosomatic Res 53: 865-871.
48. Tsou K., Mackie K., Sanudo-Pena MC, Walker JM (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93: 969-975.
49. Uriguen L., Perez-Rial S., Ledent C., Palomo T., Manzanares J. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973.
50. Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342.
51. Weidenfeld J., Feldman S., Mechoulam R. (1994) Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59: 110-112.